New research reveals that manufacturers could sell generic versions of Novo Nordisk’s blockbuster drugs, Ozempic and Wegovy, for less than $3 a month. This study highlights a massive gap between current list prices and actual production costs. It suggests a future where powerful weight-loss treatments are accessible to billions. The Massive Gap In Generic Semaglutide Pricing Researchers at the University…
Tag: Pharmaceutical Industry
-
Pfizer Drug Pricing Deal Sees Stocks Soar
In a move heralded by President Donald Trump as a monumental victory for American consumers, pharmaceutical giant Pfizer has agreed to a deal that promises to slash the prices of some of its drugs. However, the market’s reaction has told a very different story. This reaction raises questions about the actual impact of the agreement on the firm’s bottom line…
-
Pharma Giants Sidelined in R15.5bn HIV Drug Tender
The National Department of Health has awarded its latest three-year antiretroviral (ARV) tender, valued at R15.5 billion. This decision leaves several of South Africa’s largest domestic pharmaceutical manufacturers without a contract. The government’s procurement strategy sidelines pharma giants and sparks a fresh debate. This debate pits aggressive cost-saving measures against its stated goal of bolstering local industrial capacity. The tender…
-
NUMSA Agreement Secures Pharmaceutical Worker Pay Increases
The National Union of Metalworkers of South Africa (Numsa) has successfully negotiated a two-year wage agreement with employers in the nation’s burgeoning pharmaceutical sector. This negotiation secures significant pay increases and improved benefits for approximately 10,000 workers. The NUMSA agreement averts potential industrial action. It brings stability to a market projected to generate revenues of $3.47 billion in 2025. Details…
-
Trump’s Tariff Stick Won’t Bring Generic Drug Manufacturing Home
President Donald Trump’s administration has championed Trump’s Tariff Stick as a means to compel global industries to relocate manufacturing to the United States. However, for the generic drug sector, which supplies roughly 90% of all medicines consumed by Americans, Trump’s Tariff Stick is a blunt instrument with potentially damaging outcomes. Industry leaders are cautioning that, instead of encouraging domestic production,…
-
Adcock Ingram’s Lenbucod Blocked by Court Ruling
The Pretoria High Court has dealt pharmaceutical giant Adcock Ingram a significant blow, ordering the company to cease selling and distributing its new painkiller, Lenbucod. This ruling effectively blocks Adcock Ingram’s Lenbucod from the market. The court found that the name infringed upon rival Aspen Pharmaceuticals’ existing trademark, Mybucod. This legal skirmish between the two JSE-listed heavyweights highlights the increasing…
-
Adcock Ingram’s Urizone Wins Trademark Battle
A South African court has ruled in favour of Adcock Ingram and Zambon SPA. It ordered Cipla Medpro to stop using the trademark Furizome for its urinary tract infection (UTI) medication. The court found Furizome to be confusingly similar to the established Urizone trademark, central to Adcock Ingram’s branding strategy. This led to a ruling based on trademark infringement and…
-
Pharmaceutical industry fights to shield drugs from tariffs
Pharmaceutical giants are actively lobbying the Trump administration and European Union officials to exclude medical goods from escalating trade disputes. They fear significant price increases and restricted patient access to essential medications. The industry’s concerns centre on the potential impact of tariffs on top-selling drugs like Novo Nordisk’s Wegovy for weight loss and Merck’s cancer immunotherapy Keytruda. In discussions with…
-
SAHPRA calls for Increased National Treasury funding
The SA Health Products Regulatory Authority (SAHPRA) is again seeking additional financial support from the National Treasury. Over-reliance on fee income has placed the authority in a precarious position, with CEO Boitumelo Semete stressing the risks involved during a recent presentation to parliament. The authority’s diminishing government grant and industry consolidation threaten its ability to function effectively. SAHPRA, established in…